Galecto Reports Third Quarter Operating and Financial Results
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended September 30, 2022.
“The recent release of positive results from two clinical trials, our Phase 1b/2a GULLIVER-2 trial in decompensated liver cirrhosis and our Phase 2a MYLOX-1 trial in myelofibrosis, has created significant momentum for Galecto and our team,” said Galecto CEO Hans T. Schambye, M.D., Ph.D. “Galectin-3 and LOXL2 play a central role in fueling key pathological pathways in fibrosis, and the encouraging results from both of these trials provides further evidence and strengthens our belief that the inhibition of galectin-3 and LOXL2 are crucial to reducing fibrosis and potentially modifying disease. We look forward to 2023, where we expect to announce top-line results from our Phase 2b GALACTIC-1 trial in idiopathic pulmonary fibrosis (IPF) in mid-2023 and our Phase 2a GALLANT-1 trial in non-small cell lung cancer (NSCLC) in the second half of 2023.”
Recent Highlights
- Highlighted by two late-breaking presentations at the AASLD Liver Meeting® 2022, announced positive top-line results from the Phase 1b/2a GULLIVER-2 trial of GB1211, Galecto’s first-in-class, oral small molecule galectin-3 inhibitor candidate, where GB1211 demonstrated a favorable tolerability profile and showed reduced signs of liver impairment in patients with decompensated cirrhosis.
- Announced positive intermediate assessment results from the ongoing Phase 2a MYLOX-1 trial of GB2064, Galecto’s first-in-class, LOXL2 inhibitor candidate, for the treatment of myelofibrosis, where four out of five evaluable patients who received GB2064 for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, an improvement suggesting that GB2064 could impact the progression of the disease and be disease modifying.
- Poster presentation highlighting results from the intermediate assessment of the MYLOX-1 trial to be featured at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on December 10-13, 2022 in New Orleans, LA.
- Expanded Galecto’s oncology reach by entering into a collaboration agreement for an investigator-initiated Phase 2 trial with Providence Cancer Institute to evaluate GB1211 in combination with pembrolizumab (Keytruda®) in patients with metastatic melanoma and head and neck squamous cell carcinoma (HNSCC).
- Published article in the September 2022 Journal of Medicinal Chemistry demonstrating that GB1211, the first orally available galectin-3 inhibitor for the treatment of fibrotic disease, is a potent inhibitor of liver and lung fibrosis in both in vitro and in vivo models.
Expected Upcoming Milestones
- Top-line results from Phase 2b GALACTIC-1 trial (IPF) in mid-2023.
- Interim safety data from Phase 2a GALLANT-1 trial (NSCLC) by Q1 2023.
- Initiation of Phase 2 investigator-initiated GB1211 oncology trial (melanoma and HNSCC) by Providence Cancer Institute in 2023.
Third Quarter 2022 Financial Highlights
Cash, cash equivalents, and investments as of September 30, 2022 were approximately
Research and development expenses were
General and administrative expenses were
Net loss attributable to common stockholders for the three months ended September 30, 2022 was
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 inhibitor (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a recently completed Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in combination with atezolizumab (Tecentriq®) in a separate Phase 2a trial for the treatment of NSCLC.
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s ability to make progress across its clinical pipeline of assets; Galecto’s plans for timing of initiating and planned readouts of its clinical trials; the potential of Galecto’s product candidates to address significant areas of unmet need; and Galecto’s expectation that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital requirements into the second half 2024. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with the Securities and Exchange Commission (SEC), including, but not limited to, Galecto’s Annual Report on Form 10-K, as filed with the SEC on February 17, 2022. These forward-looking statements represent Galecto's judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
For more information, contact:
| Galecto, Inc. | |
| Hans Schambye, CEO Jon Freve, CFO | |
| +45 70 70 52 10 | |
| Investors/US | Media/EU |
| Ashley R. Robinson arr@lifesciadvisors.com | Sandya von der Weid svonderweid@lifesciadvisors.com |
| +1 617 430 7577 | +41 78 680 0538 |
Financial Tables to Follow
GALECTO, INC.
Condensed Consolidated Balance Sheets
(in thousands)
| September 30, | December 31, | ||||
| 2022 | 2021 | ||||
| (unaudited) | |||||
| Cash and cash equivalents | $ | 28,336 | $ | 62,563 | |
| Marketable securities | 40,748 | 37,628 | |||
| Prepaid expenses and other current assets | 2,115 | 9,911 | |||
| Marketable securities, noncurrent | 6,829 | 9,048 | |||
| Operating lease right-of-use assets | 852 | 834 | |||
| Other assets, noncurrent | 3,145 | 2,231 | |||
| Total assets | $ | 82,025 | $ | 122,215 | |
| Current liabilities | $ | 8,858 | $ | 4,544 | |
| Operating lease liabilities, noncurrent | 440 | 448 | |||
| Total liabilities | 9,298 | 4,992 | |||
| Total stockholders’ equity | 72,727 | 117,223 | |||
| Total liabilities and stockholders' equity | $ | 82,025 | $ | 122,215 | |
GALECTO, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 10,494 | $ | 9,748 | $ | 37,436 | $ | 28,373 | |||||||
| General and administrative | 3,128 | 3,191 | 10,246 | 10,386 | |||||||||||
| Total operating expenses | 13,622 | 12,939 | 47,682 | 38,759 | |||||||||||
| Loss from operations | (13,622 | ) | (12,939 | ) | (47,682 | ) | (38,759 | ) | |||||||
| Total other income (expense), net | (108 | ) | 243 | 127 | 416 | ||||||||||
| Net loss | $ | (13,730 | ) | $ | (12,696 | ) | $ | (47,555 | ) | $ | (38,343 | ) | |||
| Net loss per common share, basic and diluted | $ | (0.54 | ) | $ | (0.50 | ) | $ | (1.88 | ) | $ | (1.52 | ) | |||
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 25,491,786 | 25,261,832 | 25,342,153 | 25,261,832 | |||||||||||
| Other comprehensive gain (loss), net of tax | (426 | ) | (335 | ) | (1,605 | ) | (763 | ) | |||||||
| Total comprehensive loss | $ | (14,156 | ) | $ | (13,031 | ) | $ | (49,160 | ) | $ | (39,106 | ) | |||
